Literature DB >> 10091406

(TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome.

A Iolascon1, M F Faienza, M Centra, S Storelli, L Zelante, A Savoia.   

Abstract

BACKGROUND AND
OBJECTIVE: Gilbert's syndrome, a chronic non-hemolytic unconjugated hyperbilirubinemia, is caused by a reduction in the activity of hepatic bilirubin UDP-glucuronosyltransferase (UGT1A1). This reduction has been shown to be due to a polymorphism in the promoter region of the UGT1A1 gene. The presence of seven thymine adenine (TA) repeats reduces the efficiency of transcription of the UGT1A1 gene. To elucidate the genetic background of a patient affected by Gilbert's syndrome, we collected blood samples from family members for the analysis of the A(TA)nTAA motif in the promoter region of the UGT1A1 gene. DESIGN AND METHODS: Analysis of the A(TA)nTAA motif in the promoter region of the UGT1A1 gene was performed by PCR. Estimation of UGT1A1 promoter containing the variable (TA) repeats was performed by using a luciferase reporter system.
RESULTS: Three different genotypes were identified due to the presence of (TA)6, (TA)7 and (TA)8 repeats. The production of luciferase decreases in inverse relation to the number of repeats. INTERPRETATION AND
CONCLUSIONS: The (TA)7 polymorphism, associated with Gilbert syndrome, is the only allele found up to now in white populations, while two other variants (TA)5 and (TA)8 have been identified in black populations. We describe here the first case of a subject affected by Gilbert's syndrome who is heterozygous for the (TA)8 allele in the promoter region of the UGT1A1 gene. This polymorphism, as well as the (TA)7 one, is associated with an increased level of bilirubin and a significant reduction of transcription activity of the UGT1A1 gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10091406

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  11 in total

Review 1.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.

Authors:  Camilla Stormo; Martin P Bogsrud; Monica Hermann; Anders Åsberg; Armin P Piehler; Kjetil Retterstøl; Marianne K Kringen
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

4.  Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome.

Authors:  Carsten Skarke; Helmut Schmidt; Gerd Geisslinger; Jutta Darimont; Jörn Lötsch
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

5.  Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

Authors:  Renee M Balliet; Gang Chen; Carla J Gallagher; Ryan W Dellinger; Dongxiao Sun; Philip Lazarus
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

6.  Multiple variants in UGT1A1 gene are factors to develop indirect hyper-bilirubinemia.

Authors:  Rei-Ting Hu; Nai-Yuan Wang; May-Jen Huang; Ching-Shan Huang; Ding-Shinn Chen; Sien-Sing Yang
Journal:  Hepatobiliary Surg Nutr       Date:  2014-08       Impact factor: 7.293

7.  Genetic polymorphisms in human SULT1A1 and UGT1A1 genes associate with breast tumor characteristics: a case-series study.

Authors:  Ekaterina G Shatalova; Susan E Walther; Olga O Favorova; Timothy R Rebbeck; Rebecca L Blanchard
Journal:  Breast Cancer Res       Date:  2005-09-21       Impact factor: 6.466

Review 8.  Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview.

Authors:  Chantal Guillemette; Alain Bélanger; Johanie Lépine
Journal:  Breast Cancer Res       Date:  2004-09-27       Impact factor: 6.466

9.  UGT1A1*28 relationship with abnormal total bilirubin levels in chronic hepatitis C patients: Outcomes from a case-control study.

Authors:  Marcelo Moreira Tavares de Souza; Victor Van Vaisberg; Rodrigo Martins Abreu; Aline Siqueira Ferreira; Camila daSilvaFerreira; Paulo Dominguez Nasser; Helena Scavone Paschoale; Flair José Carrilho; Suzane Kioko Ono
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

10.  UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease.

Authors:  Zainab Hamad; Abdullah Aljedai; Rabih Halwani; Abdulrahman AlSultan
Journal:  Ann Saudi Med       Date:  2013 Jul-Aug       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.